GRIDAI TECHNOLOGIES CORP (GRDX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.25+9.43%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GRDX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||
| Revenues | — | 0.0 | — | — | — | — | 0.0 | 0.0 | — | — | — |
| Total Revenues | — | — | — | — | — | — | — | 0.0 | — | — | — |
| Cost of Revenues | — | 0.7 | — | — | — | — | — | — | — | — | — |
| Gross Profit | — | (0.7) | — | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | |||||||||||
| R&D Expenses | 1.5 | 0.9 | 0.9 | 5.0 | 8.8 | 17.0 | 5.9 | 8.7 | 5.8 | 2.4 | 2.5 |
| Operating Income | (22.3) | (7.1) | (15.6) | (15.8) | (12.7) | (59.1) | (26.4) | — | (13.4) | (10.2) | (6.3) |
| Earnings from Continuing Operations | |||||||||||
| Interest Expense | — | — | — | 0.0 | 0.0 | 0.0 | 5.8 | 0.4 | 0.1 | 0.9 | 5.9 |
| Interest & Investment Income | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — |
| Net Interest Expenses | — | — | — | 0.0 | 0.0 | 0.0 | 5.8 | — | — | — | — |
| Other Non-Operating Income / Expenses | 0.5 | 0.4 | 0.0 | (0.0) | (2.0) | 0.5 | (6.2) | — | — | — | — |
| Asset Writedown | — | — | — | 0.0 | 0.0 | 0.0 | — | — | — | — | — |
| EBT, Incl. Unusual Items | (21.8) | (6.6) | — | — | — | — | (32.7) | — | — | (11.1) | (14.6) |
| Income Tax Expense | — | (0.4) | — | — | — | 0.0 | 0.0 | — | — | 0.0 | 0.0 |
| Earnings from Continuing Operations | — | (6.2) | — | — | — | — | — | — | — | — | — |
| Net Income | |||||||||||
| Minority Interest | — | (0.2) | — | — | — | — | — | — | — | — | — |
| Net Income | (20.6) | (6.4) | (18.1) | (15.8) | (14.6) | (58.5) | (32.7) | (15.2) | (13.5) | (11.1) | (14.6) |
| Per Share | |||||||||||
| Basic EPS | (3.21) | (4.16) | (5.33) | (47.88) | (416.94) | — | (14.68) | — | — | — | — |
| Diluted EPS | (3.21) | (4.16) | (5.33) | (47.88) | (416.94) | — | (14.68) | — | — | — | — |
| Basic Weighted Avg Shares | 6.4 | 1.6 | 3.4 | 0.3 | 0.0 | 0.0 | 2.8 | — | — | — | — |
| Diluted Weighted Avg Shares | 6.4 | 1.6 | 3.4 | 0.3 | 0.0 | 0.0 | 2.8 | — | — | — | — |
| Supplemental | |||||||||||
| EBITDA | — | (6.5) | (15.6) | (15.7) | (12.6) | (59.0) | (26.4) | — | — | — | — |
| EBIT | (22.3) | (7.1) | (15.6) | (15.8) | (12.7) | (59.1) | (26.4) | — | (13.4) | (10.2) | (6.3) |
| Effective Tax Rate | — | — | — | — | — | — | 0.0% | — | — | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.